30 September 2008

Further to the news article on October 10th 2007 about Ondine and UCL’s collaborative breakthrough Staphyloccocal Photodisinfection Technology, UCL Business is delighted to have concluded an exclusive licence with Ondine for the human therapeutic use of a gold-nanoparticle photosensitizer from UCL.

In conjunction with the important ongoing collaborative effort, this compound could herald a major new development in the struggle against MRSA.

“In vitro studies have shown that this advanced compound is one of the most potent photodisinfection agents ever developed. The compound has proven highly efficacious in killing Methicillin/multi-drug Resistant Staphylococcus Aureus, (MRSA), a prominent hospital-acquired pathogen,” states Dr. Nicolas Loebel, Ondine’s Chief Technology Officer. “We intend to further develop this new agent for integration into our Photodisinfection System for various medical applications such as in-situ catheter disinfection and the eradication of microorganisms in burns, wounds and surgical site incisions.”

About Ondine Biopharma Corporation
Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on creating and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is headquartered in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, USA, and an international office in St. Michael, Barbados.

For additional information, please visit the Company’s website at: www.ondinebiopharma.com

Further Information
For further information contact Derek Reay, Snr Business Manager, UCL Business PLC on 020 7679 9000, d.reay@uclb.com.